Wound Healing News and Research

RSS

Researchers describe preparation of chitosan nanoparticles

Nanoparticles containing chitosan have been shown to have effective antimicrobial activity against Staphylococcus saprophyticus and Escherichia coli. The materials could be used as a protective wound-healing material to avoid opportunistic infection as well as working to facilitate wound healing.

17 Mar 2012

Third International Symposium on Thymosins in Health and Disease to take place on GW campus

The George Washington University is host to the world's leaders in the area of research that focuses on Thymosins- small proteins present in many animal tissues that have diverse biological activities- Two in particular, thymosins α1 and β4, have potentially important uses in medicine, and research has already progressed from the laboratory to the clinic.

16 Mar 2012

Study provides insight into developing new treatment strategies for triple-negative breast cancer

A new study by University of Kentucky researchers provides insight into developing new treatment strategies for basal-like breast cancer, commonly known as triple-negative breast cancer. This cancer is associated with early metastasis and resistance to chemotherapy and occurs at women at a younger age.

15 Mar 2012

Researchers identify epigenetic signatures within reprogrammed skin cells

A research team has identified epigenetic signatures, markers on DNA that control transient changes in gene expression, within reprogrammed skin cells.

15 Mar 2012

FDA approves Organogenesis oral soft tissue regeneration product, GINTUIT

Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue).

12 Mar 2012

Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%.

7 Mar 2012

External cues affect cell's ability to migrate

In a paper published today in the journal, Cell, a team from the University of North Carolina at Chapel Hill has explained for the first time how a long-studied protein complex affects cell migration and how external cues affect cell's ability to migrate.

2 Mar 2012

Combined bioactive peptides successfully stimulate wound healing

Researchers have combined bioactive peptides to successfully stimulate wound healing. The in vitro and in vivo study, published today in PLoS ONE, demonstrates that the combination of two peptides stimulates the growth of blood vessels and promotes re-growth of tissue. Further development of these peptides could lead to a new treatment for chronic and acute wounds.

24 Feb 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

Osiris provides update on status of development, commercialization agreement with Genzyme

Osiris Therapeutics, Inc., today provided an update on the status of the development and commercialization agreement with Genzyme, a Sanofi company.

10 Feb 2012

Three new targeted drugs can lead to fatal cancer complications

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients.

7 Feb 2012

Small molecules at cell's membrane enable cell movement

Cell biologists at Johns Hopkins have identified key steps in how certain molecules alter a cell's skeletal shape and drive the cell's movement.

3 Feb 2012

Small molecules at the cell’s membrane enable cell movement

Cell biologists at Johns Hopkins have identified key steps in how certain molecules alter a cell’s skeletal shape and drive the cell’s movement.

31 Jan 2012

USPTO issues patent to SANUWAVE's new method that produces acoustic shock waves

SANUWAVE Health, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled "Method and Apparatus for Producing Shock Waves for Medical Applications."

18 Jan 2012

New online publication on wound care

The rapidly advancing field of tissue injury and repair has an important new forum. Advances in Wound Care will report the latest research findings, innovative wound care strategies, industry product pipeline, and developments in biomaterials and skin and tissue regeneration to optimize patient outcomes.

11 Jan 2012

Intestinal worm infections may not be bad

Intestinal worm infections may not be all bad, according to a new study by William C. Gause, PhD, and colleagues at UMDNJ- New Jersey Medical School. The researchers have found cytokines that help oust intestinal worm infections in mice also soothe associated lung injury and inflammation.

11 Jan 2012

New possibilities for effective treatment of psoriasis

Researchers at Link-ping University in Sweden are now launching a plan to effectively treat psoriasis.

11 Jan 2012

SANUWAVE PACE technology reverses negative effects of ischemic, reperfusion injuries

SANUWAVE Health, Inc., today reported publication of peer-reviewed, preclinical data conducted at Cleveland Clinic that demonstrate the ability of the Company's Pulsed Acoustic Cellular Expression (PACE®) technology to substantially decrease the detrimental effects of microcirculatory injury for certain ischemic (lack of blood flow) and reperfusion (restoration of blood flow) injuries.

11 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

New Zealand life science and health IT companies to showcase their products in San Francisco

New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand life sciences companies who have reached key stages in their development are joining the throngs of international therapeutics, medical device and health IT companies in San Francisco, January 9 - 12 to showcase their products and capabilities to potential corporate partners and investors.

7 Jan 2012